共 50 条
- [11] TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burdenLANCET GLOBAL HEALTH, 2024, 12 (02): : e179 - e180Wilder-Smith, Annelies
- [12] Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experiencePLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (08):Fernando, LakKumarKastner, RandeeWickramasinghe, PujithaFernando, Asvini D.Gunasekera, DulanieNguyen, Van HungLiu, MengyaLeFevre, IngeWallace, DerekFolschweiller, NicolasBiswal, Shibadas
- [13] MODELING THE IMPACT OF THE VACCINE CANDIDATE TAK-003 ON THE INCIDENCE OF DENGUE IN FRENCH OVERSEAS TERRITORIESVALUE IN HEALTH, 2023, 26 (12) : S211 - S211Nucit, A.Moreau, R.Massetti, M.Strub, C.Kharitonova, E.Tytula, A.Zawieja, J.Leleu, H.Shen, J.
- [14] Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (03):White, Laura J.Young, Ellen F.Stoops, Mark J.Henein, Sandra R.Adams, Elizabeth C.Baric, Ralph S.de Silva, Aravinda M.
- [15] A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic countryVACCINE, 2023, 41 (07) : 1398 - 1407Tricou, VianneyEyre, SusannahRamjee, MahadevMojares, ZenaidaCollini, PaulLoeliger, EddeMandaric, SanjaRauschera, MartinaBrose, ManjaLefevre, IngeFolschweiller, NicolasWallace, Derek
- [16] Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : 107 - 117Rivera, LuisBiswal, ShibadasSaez-Llorens, XavierReynales, HumbertoLopez-Medina, EduardoBorja-Tabora, CharissaBravo, LuluSirivichayakul, ChukiatKosalaraksa, PopeMartinez Vargas, LuisYu, DeliaWatanaveeradej, VeerachaiEspinoza, FelixDietze, ReynaldoFernando, LakKumarWickramasinghe, PujithaDuarte Moreira Jr, EdsonFernando, Asvini D.Gunasekera, DulanieLuz, KleberVenancioda Cunha, RivaldoRauscher, MartinaZent, OlafLiu, MengyaHoffman, ElaineLeFevre, IngeTricou, VianneyWallace, DerekAlera, Maria TheresaBorkowski, Astrid
- [17] Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003FRONTIERS IN IMMUNOLOGY, 2019, 10 : 1778Waickman, Adam T.Friberg, HeatherGargulak, MorganKong, AmandaPolhemus, MarkEndy, TimothyThomas, Stephen J.Jarman, Richard G.Currier, Jeffrey R.
- [18] Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after VaccinationJOURNAL OF INFECTIOUS DISEASES, 2022, 225 (09): : 1521 - 1532Lopez-Medina, EduardoBiswal, ShibadasSaez-Llorens, XavierBorja-Tabora, CharissaBravo, LuluSirivichayakul, ChukiatMartinez Vargas, LuisTheresa Alera, MariaVelasquez, HectorReynales, HumbertoRivera, LuisWatanaveeradej, VeerachaiJohana Rodriguez-Arenales, EdithYu, DeliaEspinoza, FelixDietze, ReynaldoFernando, Lak KumarWickramasinghe, PujithaDuarte Moreira, EdsonFernando, Asvini D.Gunasekera, DulanieLuz, KleberVenancio da Cunha, RivaldoTricou, VianneyRauscher, MartinaLiu, MengyaLeFevre, IngeWallace, DerekKosalaraksa, PopeBorkowski, Astrid
- [19] Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adultsVACCINE, 2023, 41 (47) : 6999 - 7006Tricou, VianneyWinkle, Peter J.Tharenos, Leslie M.Rauscher, MartinaEscudero, IanHoffman, ElaineLeFevre, IngeBorkowski, AstridWallace, Derek